US 11,744,807 B2
Therapeutic compositions and methods for pulmonary fibrosis
Muhammed Majeed, Bangalore (IN); Kalyanam Nagabhushanam, East Windsor, NJ (US); Sarang Bani, Bangalore (IN); and Anjali Pandey, Bangalore (IN)
Assigned to SAMI-SABINSA GROUP LIMITED, Bangalore (IN)
Filed by Muhammed Majeed, Bangalore (IN); Kalyanam Nagabhushanam, East Windsor, NJ (US); Sarang Bani, Bangalore (IN); and Anjali Pandey, Bangalore (IN)
Filed on Jan. 17, 2021, as Appl. No. 17/151,172.
Claims priority of provisional application 62/962,343, filed on Jan. 17, 2020.
Prior Publication US 2021/0220291 A1, Jul. 22, 2021
Int. Cl. A61K 31/122 (2006.01); A61P 11/00 (2006.01); A61K 31/09 (2006.01); A61K 47/10 (2017.01); A61K 36/9066 (2006.01)
CPC A61K 31/122 (2013.01) [A61K 31/09 (2013.01); A61K 36/9066 (2013.01); A61K 47/10 (2013.01); A61P 11/00 (2018.01)] 5 Claims
 
1. A method for therapeutic management of pulmonary fibrosis in a mammal in need thereof, said method comprising the step of administering a composition comprising isogarcinol or a combination of isogarcinol and octahydrocurcumin to the mammal to bring about a reduction in symptoms and features of pulmonary fibrosis.